Company developing patient-specific immunotherapies for cancer.
At BioNTech we understand that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized.
To pioneer the next generation of patient-specific immunotherapies, we have combined ground-breaking research with cutting-edge technologies to develop therapeutics for cancer and beyond. Our broad and synergistic suite of platforms, which include mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators have been optimized for distinct modes of action, high precision targeting, high potency and efficacy. We are also developing in parallel our own state-of-the-art manufacturing processes to complement our drug development platforms.
Visit website: https://biontech.de/